Brenard R
Hôpital St Joseph, Gilly, Bruxelles.
Acta Gastroenterol Belg. 1997 Jul-Sep;60(3):211-3.
Interferon alpha is currently used in chronic hepatitis and side effects are well known. They always must be kept in mind to start and to follow a patient under this therapy. A large number of autoantibodies may appear during interferon therapy, usually without clinical manifestations. The detection of dysthyroidism, requires measurement of antithyroid antibodies and TSH before and during interferon therapy. Exacerbation of chronic liver disease under IFN may be found in case of seroconversion in a patient with hepatitis B cirrhosis or in patient with a misdiagnosis of autoimmune hepatitis. Neurolopsychological disturbances are frequently reported; most of them spontaneously disappear. However, depression must be detected because of the risk of attempted or successful suicide. Worsening or sudden onset of psoriasis or lichen planus have been reported in patients treated with interferon. Appearance or aggravation of some clinical symptoms and biochemical tests may threaten life's patient under IFN therapy. The decision to maintain or to interrupt therapy should take into account the response to interferon and the severity of side effect.
干扰素α目前用于治疗慢性肝炎，其副作用众所周知。在开始并对接受该疗法的患者进行随访时，必须始终牢记这些副作用。在干扰素治疗期间可能会出现大量自身抗体，通常无临床表现。对于甲状腺功能障碍的检测，需要在干扰素治疗前及治疗期间测定抗甲状腺抗体和促甲状腺激素（TSH）。在乙型肝炎肝硬化患者发生血清学转换或自身免疫性肝炎误诊患者中，可能会出现干扰素治疗下慢性肝病的恶化。经常有神经心理障碍的报告；其中大多数会自发消失。然而，由于存在自杀未遂或自杀成功的风险，必须检测出抑郁症。在用干扰素治疗的患者中，有银屑病或扁平苔藓病情恶化或突然发作的报告。某些临床症状和生化检查结果的出现或加重可能会威胁接受干扰素治疗患者的生命。维持或中断治疗的决定应考虑对干扰素的反应以及副作用的严重程度。
